» Articles » PMID: 18579139

Obstetric Outcomes Following Vitrification of in Vitro and in Vivo Matured Oocytes

Overview
Journal Fertil Steril
Date 2008 Jun 27
PMID 18579139
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate obstetric outcomes with oocyte vitrification after ovarian stimulation (OS) and in vitro maturation (IVM) of immature oocytes.

Design: A prospective trial from October 2003 to April 2007.

Setting: University-based medical center.

Patient(s): OS group: 38 patients undergoing intrauterine insemination who overresponded to OS. IVM group: 20 patients who had previous unsuccessful intrauterine insemination.

Intervention(s): Mature oocyte retrieval following OS. Immature oocyte retrieval and IVM. Oocyte vitrification, thawing, insemination, and transfer of the resulting embryos.

Main Outcome Measure(s): Live-birth rates and obstetric outcomes.

Result(s): The OS group was superior to the IVM group in terms of oocyte survival (81.4 +/- 22.6% vs. 67.5 +/- 26.1%), fertilization rate (75.6 +/- 22.5% vs. 64.2 +/- 19.9%), and cumulative embryo score (38.4 +/- 22.3 vs. 20.0 +/- 13.8). However, the differences in the implantation rate per embryo (19.1 +/- 25.8% vs. 9.6 +/- 24.1%), clinical pregnancy rate per cycle started (44.7%, vs. 20.0%), and live-birth rate per cycle started (39.5% vs. 20.0%) were not statistically significant. Twenty healthy babies were born in the OS group and four in the IVM group.

Conclusion(s): Pregnancies achieved with vitrification of oocytes after OS and IVM treatments do not appear to be associated with adverse pregnancy outcomes. Vitrification of IVM oocytes represents a novel option for fertility preservation.

Citing Articles

Live birth after vitrification of oocytes from capacitation in vitro maturation.

Le X, Nguyen D, Nguyen T, Le T, Vuong L, Ho T J Assist Reprod Genet. 2024; 41(8):1985-1989.

PMID: 38990423 PMC: 11339008. DOI: 10.1007/s10815-024-03200-y.


Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases.

Saito S, Yamada M, Yano R, Takahashi K, Ebara A, Sakanaka H J Ovarian Res. 2023; 16(1):159.

PMID: 37563616 PMC: 10416401. DOI: 10.1186/s13048-023-01250-x.


IVM of human immature oocytes for infertility treatment and fertility preservation.

Chian R, Li J, Lim J, Yoshida H Reprod Med Biol. 2023; 22(1):e12524.

PMID: 37441160 PMC: 10335168. DOI: 10.1002/rmb2.12524.


Fertility preservation strategies for cancerous women: An updated review.

Anbari F, Khalili M, Mahaldashtian M, Ahmadi A, Palmerini M Turk J Obstet Gynecol. 2022; 19(2):152-161.

PMID: 35770454 PMC: 9249358. DOI: 10.4274/tjod.galenos.2022.42272.


Effect of double embryo transfer derived from autologous frozen oocytes on multiple pregnancy rates and presentation of success rates stratified by age at retrieval.

Badeghiesh A, Konci R, Aldhaheri S, Son W, Dahan M J Turk Ger Gynecol Assoc. 2021; 22(3):168-173.

PMID: 34109775 PMC: 8420741. DOI: 10.4274/jtgga.galenos.2021.2020.0207.